Overall, this study has demonstrated that patients on apixaban and rivaroxaban will have no effect on thrombophilia assays (protein S, protein C and ATIII), patients on dabigatran may cause interference with thrombophilia assays (protein S and/or ATIII) and lupus anticoagulant tests are affected by all three DOACs. This evidence concerns the gene PROS1 and systemic lupus erythematosus.